| G02CB |
G02CB Prolactine inhibitors |
| G02CB01 |
G02CB01 Bromocriptine |
| G02CB02 |
G02CB02 Lisuride |
| G02CB03 |
G02CB03 Cabergoline |
| G02CB04 |
G02CB04 Quinagolide |
| G02CB05 |
G02CB05 Metergoline |
| G02CB06 |
G02CB06 Terguride |
| G02CC |
G02CC Anti-inflammatory products for vaginal administration |
| G02CC01 |
G02CC01 ibuprofen |
| G02CC02 |
G02CC02 Naproxen |
| G02CC03 |
G02CC03 Benzydamine |
| G02CC04 |
G02CC04 Flunoxaprofen |
| G02CX |
G02CX Other gynecologicals |
| G02CX01 |
G02CX01 Atosiban |
| G02CX02 |
G02CX02 Flibanserin |
| G02CX03 |
G02CX03 Agni casti fructus |
| G02CX04 |
G02CX04 Cimicifugae rhizoma |
| G02CX05 |
G02CX05 Bremelanotide |
| G02CX06 |
G02CX06 Fezolinetant |
| G02CX07 |
G02CX07 Elinzanétant |
| G03 |
G03 Sex hormones and modulators of the genital system |
| G03A |
G03A Hormonal contraceptives for systemic use |
| G03AA |
G03AA Progestogens and estrogens, fixed combinations |
| G03AA01 |
G03AA01 Etynodiol and ethinylestradiol |
| G03AA02 |
G03AA02 Quingestanol and ethinylestradiol |
| G03AA03 |
G03AA03 Lynestrenol and ethinylestradiol |
| G03AA04 |
G03AA04 Megestrol and ethinylestradiol |
| G03AA05 |
G03AA05 Norethisterone and ethinylestradiol |
| G03AA06 |
G03AA06 Norgestrel and ethinylestradiol |
| G03AA07 |
G03AA07 Levonorgestrel and ethinylestradiol |